---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-004328"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T17:13:41.166870+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology reports 2022 net loss of $15.7M; cash $10.9M; Phase 2 NSCLC trial underway in Europe

## Summary
- Net loss $15.7M for 2022 vs $12.6M in 2021; R&D expenses $8.9M (up from $3.5M) due to THIO trial startup.
- Cash $10.9M at Dec 31, 2022 vs $10.6M at Dec 31, 2021; G&A expenses $6.1M (up from $4.3M) including $1.1M ratchet share expense.
- First two patients dosed in Phase 2 THIO-101 trial in Europe for advanced NSCLC; plan to initiate second Phase 2 trial THIO-102.
- Pre-IND meeting with FDA for U.S. expansion; positive feedback on manufacturing and clinical development plan.
- Preclinical data presented at SITC for THIO in hepatocellular carcinoma; new telomere-targeting molecule program advanced.

## SEC filing metadata
- accession: 0001564590-23-004328
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/0001564590-23-004328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/maia-8k_20230324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-004328
- JSON: https://secwatch.observer/filing/0001564590-23-004328.json
- Plain text: https://secwatch.observer/filing/0001564590-23-004328.txt

## Key facts
- Earnings Releases
  MAIA Biotechnology, Inc. reported for the year ended December 31, 2022 results: net income approximately $15.7 million.
  - Period: for the year ended December 31, 2022
  - Net income: approximately $15.7 million
  - Result: reported results
  source text: Net loss was approximately $15.7 million for the year ended December 31, 2022, as compared to net loss of approximately $12.6 million for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/0001564590-23-004328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.